BioSpace

Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosion

Bracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.

By BioSpace

1 min read
Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosion
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights